Immatics N.V.IMTX

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Germany · immatics.com

Immatics is a clinical-stage biopharmaceutical company (Tuebingen, Germany and Houston, TX) developing TCR-based cell therapies and TCR bispecifics targeting PRAME and other cancer antigens.

Key ratios

Operating cash flow growth

-81.8%2023

FCF / Sales

-379.5%2025

2024 -111.9%2023 -23.3%

Net margin

-141.6%TTM

2024 9.8%2023 -175.3%

ROA

-18.1%2025

2024 -4.0%2023 -13.9%

ROE

-37.1%2025

2024 3.8%2023 -45.0%

Revenue growth

-69.0%2025

2024 188.6%2023 -68.8%

Recent news

Immatics Announces $150 Million Underwritten Offering 2026-08-25 · GlobeNewswire

Track IMTX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer